OP Asset Management Ltd Purchases Shares of 12,915 Guardant Health, Inc. $GH

OP Asset Management Ltd acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,915 shares of the company’s stock, valued at approximately $1,193,000.

Several other institutional investors have also added to or reduced their stakes in GH. V Square Quantitative Management LLC bought a new position in Guardant Health during the 4th quarter worth about $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the fourth quarter valued at approximately $35,000. Finally, Parallel Advisors LLC grew its stake in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Activity at Guardant Health

In other news, Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $255,893.16. Following the transaction, the director owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. This represents a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer owned 47,509 shares in the company, valued at approximately $6,110,607.58. This trade represents a 4.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 452,513 shares of company stock valued at $51,608,916. Insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

GH has been the topic of a number of analyst reports. Mizuho upped their price objective on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Piper Sandler set a $127.00 target price on shares of Guardant Health in a report on Thursday, May 21st. Barclays upped their price target on shares of Guardant Health from $120.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. BTIG Research set a $160.00 price objective on shares of Guardant Health and gave the company a “buy” rating in a research report on Wednesday, May 27th. Finally, Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Guardant Health currently has an average rating of “Buy” and a consensus target price of $144.82.

Guardant Health Price Performance

GH stock opened at $153.74 on Tuesday. The company has a fifty day moving average price of $113.99 and a two-hundred day moving average price of $104.38. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $153.95. The stock has a market cap of $20.39 billion, a price-to-earnings ratio of -45.35 and a beta of 1.61.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.